Activin Receptors, Type II
"Activin Receptors, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the two types of ACTIVIN RECEPTORS. They are membrane protein kinases belonging to the family of PROTEIN-SERINE-THREONINE KINASES. The major type II activin receptors are ActR-IIA and ActR-IIB.
| Descriptor ID |
D030301
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.062.750 D12.776.543.750.750.400.820.500.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Activin Receptors, Type II".
Below are MeSH descriptors whose meaning is more specific than "Activin Receptors, Type II".
This graph shows the total number of publications written about "Activin Receptors, Type II" by people in this website by year, and whether "Activin Receptors, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Activin Receptors, Type II" by people in Profiles.
-
SARS-CoV-2 infection in patients with ß-thalassemia: Experience from Lebanon. Am J Hematol. 2021 08 01; 96(8):E285-E288.
-
Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations. BMJ Case Rep. 2021 Jan 08; 14(1).
-
Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19. Angiogenesis. 2021 02; 24(1):13-15.
-
Follicular localization of growth differentiation factor 8 and its receptors in normal and polycystic ovary syndrome ovaries. Biol Reprod. 2018 05 01; 98(5):683-694.
-
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017 11 30; 8(1):1859.
-
Heritable pulmonary hypertension: from bench to bedside. Eur Respir Rev. 2017 Sep 30; 26(145).
-
Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets. 2017 10; 21(10):933-947.
-
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clin Cancer Res. 2017 Jul 15; 23(14):3557-3565.